Pathfinder Cell Therapy, Inc.
http://www.pathfindercelltherapy.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Pathfinder Cell Therapy, Inc.
Alkermes Thinks Nemvaleukin Could Succeed Where Other IL-2 Candidates Have Failed
On the heels of clinical failures for Nektar’s pegylated IL-2 candidate bempeg, Alkermes’ CEO argued its high-dose IL-2 for cancer is well differentiated during earnings call. Schizophrenia drug Lybalvi posted solid first full-quarter revenue, prescription numbers.
Finance Watch: Big VC Money Backs Tech-Enabled Drug Discovery
Private Company Edition: XtalPi raised $318.8m for its AI-based drug discovery platform and machine learning-enabled Flagship start-up Valo Health has brought in nearly $100m. XtalPi had one of three recent venture capital mega-rounds for China-based companies.
Coccidioidomycosis Outlook Highlights The Limits Of Regulatory Incentives
The US FDA heard a lot about the structural, medical and especially financial barriers facing coccidioidomycosis, or Valley fever, drug development soon after the agency refused to qualify the rare fungal infection for priority review voucher incentives.
Deals Update (09/2007)
A roundup of recent medtech strategic alliances, mergers & acquisitions and financings.
Company Information
- Industry
- Biotechnology
-
Pharmaceuticals
- Drug Delivery
-
Medical Devices
- Biomaterials
- Implantable Devices
- Other Names / Subsidiaries
-
- SyntheMed, Inc., Pathfinder
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice